Bolus Versus Continuous Remimazolam for Anesthetic Induction
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset.
Because remimazolam does not have analgesic property, it should be used with opioid during
general anesthesia. Although the incidence of hypotension is known to be low with
remimazolam, hypotension is the one of the most frequent adverse events with remimazolam.
Moreover, opioid also can lower blood pressure. Therefore, along with opioid, remimazolam can
cause hypotension after anesthetic induction.
This study is aimed to investigate the incidence of hypotension after anesthetic induction
with bolus (0.14-0.33 mg/kg) or continuous (6-12 mg/kg/hr) remimazolam administration along
with opioid use.